Company: RGBP
Filing Date: 2025-12-05
Form Type: 253G1
Source: 0001493152-25-026350
Chunk: 58

Company: Regen BioPharma Inc
Filing Date: 2025-12-05
Form: 253G1
Chunk 58
---
 |   |
|:-----------------------------------------------------|:----|--------------:|--------:|:--|:----|-----:|---------:|:--|
|                                                      |     |  December 31, |         |   |     |      |          |   |
|                                                      |     |          2024 |         |   |     | 2023 |          |   |
| Net cash used in operating activities                |     |             $ | (66,379 | ) |     |    $ | (162,336 | ) |
| Net cash provided by financing activities            |     |               |  65,799 |   |     |      |  165,797 |   |
| Net increase (decrease) in cash and cash equivalents |     |             $ |    (581 | ) |     |    $ |    3,460 |   |
| Cash, beginning of period                            |     |               |     716 |   |     |      |  121,037 |   |
| Cash, end of period                                  |     |             $ |     135 |   |     |    $ |  124,497 |   |

Operating Activities

Net cash used in operating activities for the quarter ended December 31, 2024 was $66,379, compared to $162,336, for the same period ended, 2023, a decrease of $96,256. The decrease in cash used in operating activities is primarily attributable to decreased operating expenses incurred by the Company during the quarter ended December 31, 2024 as compared to the same quarter ended 2023.

Financing Activities

Net cash generated by financing activities for the quarter ended December 31, 2024 was $65,799 which consisted of proceeds from notes payables.

Liquidity & Capital Resources Outlook

As of December 31, 2024, the Company had cash of $ 135 and net working capital of ($5,696,776)

<div align='center'>42</div>

The Company has incurred and expects to continue to incur significant professional costs to remain as a publicly traded company and it has incurred and expects to continue incur significant research & development cost for products development.

The accompanying financial statements have been prepared as if the Company will continue as a going concern. The Company has incurred significant operating losses and negative cash flows from operations since inception. As of December 31, 2024, the Company had cash of approximately $135 and an accumulated deficit